RxDoctor Payments Data

Chris Pan, MD

Cardiovascular Disease · Long Beach, CANPI 1841515509

Payments from drug & device makers

$2,159in general payments, 2019–2025

Across 60 payments — averaging $35.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$469
  • AstraZeneca$406
  • AOP Health US, LLC$268
  • Abbott$236
  • E.r. Squibb & Sons, L.L.C.$169
  • Pfizer$101
  • plus $510 from 10 others

What the payments were for

  • Food & beverage$2,06095%
  • Education$995%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,159 in reported general payments places this provider in the 45th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$40,552
Medicare patients
108
Services billed
339

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban336$364,453
EntrestoSacubitril/Valsartan170$185,058
XareltoRivaroxaban131$117,380
FarxigaDapagliflozin Propanediol142$112,710
BrilintaTicagrelor36$30,024
Dabigatran EtexilateDabigatran Etexilate Mesylate40$13,033
Metoprolol Succinate534$10,122
Repatha SureclickEvolocumab13$8,349
Ranolazine ErRanolazine37$4,426
Atorvastatin Calcium383$4,363
Diltiazem 12hr ErDiltiazem Hcl17$3,735
Amiodarone Hcl54$3,331
Furosemide470$3,183
Carvedilol249$2,801
Diltiazem 24hr Er (Xr)Diltiazem Hcl51$2,549

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$101$364,453336 claims
NovartisEntresto$62$185,058170 claims
AstraZenecaFarxiga, Brilinta$406$142,734178 claims
Johnson & JohnsonXarelto$44$117,380131 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Long Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →